Interview with Darren Ji, CEO, PharmaLegacy
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Address: Building 7, 388 Jialilue Rd.,Zhangjiang High-Tech Park, Shanghai,China
Tel: (86) 21-6100 2280
Web: http://www.pharmalegacy.com/Home.aspx?lang=en
PharmaLegacy Laboratories is a leading preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Bone Metabolism, Immune Diseases, Inflammation, Oncology, and Orthopaedics and Tissue Engineering. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirement.
Aspiring to collaborate with our global clients to accelerate their missions to develop new therapies, PharmaLegacy provides quality services with faster turnaround and higher productivity of R&D to IND/IDE endeavors for pharmaceutical, biotech, and orthopaedic device companies around the world.
The PharmaLegacy management team consists of world-renowned scholars, top service scientists and seasoned business leaders from the US and Shanghai. We have fully established animal pharmacology models of rodents, rabbits, dogs, sheep, goats and non-human primates which are used to serve our current clients of large multinational pharmaceutical and medical device companies, as well as small- to-medium-sized biotech companies.
Research
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
PharmaBoardroom sat down with more than 25 biotech CEOs in China in 2019. We analyzed the contents of the interviews and found the following recurring themes at the top of…
As patients and consumers grow more educated and proactive in managing their own health and wellbeing, new ventures are hoping to serve their needs in not just prophylactic but also…
On 26 August 2019, the Chinese legislature, the National People’s Congress (NPC), passed the new Drug Administration Law (DAL), which came into effect on 1 December 2019 and represents one…
GemPharmatech is a fast-growing service center for production, distribution and phenotyping of gene-modified mouse models with multiple subsidiaries in China, and an upcoming one in the USA. Chairman Professor Xiang…
Cancer is one of the world’s leading causes of death and in China, the globe’s most populous country, it is an ever-increasing concern. In 2018, there were approximately 4.3 million…
According to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the biggest threats to global health, food security, and development today. If this trend is not slowed or reversed,…
Within the industry, Allergan already stands out for the interesting composition of its portfolio. For China President White Wang, this was precisely the attraction. He enthuses, “Allergan is truly a…
The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market…
Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually…
Rae Yuan, president of Sinovant Sciences, shares the company’s “transformer” strategy culminating in a strong pipeline of innovative products spanning eight therapeutic areas, and their mission to serve the needs…
Hans Schmid, chairman; and Enrico Magnani, GM, of global cancer supportive care leader Helsinn Pharmaceuticals’ operations in China, share the Swiss company’s strategy in China, having entered in 2012; the…
The rate of diabetes in China has exploded: the number of diabetic patients has surpassed 100 million and is expected to increase to 150 million by 2040. Dr Qinghua Wang,…
See our Cookie Privacy Policy Here
